{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"A TEAE was defined as an adverse event (AE) that was reported for the first time or the worsening of a pre-existing event after the first dose of study treatment.","groups":[{"description":"In Phase 1, participants received oral INCB001158 75 milligrams (mg) twice daily (BID) in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.","id":"OG000","title":"Phase 1: INCB001158 75 mg BID + Daratumumab"},{"description":"In Phase 1, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.","id":"OG001","title":"Phase 1: INCB001158 100 mg BID + Daratumumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full Analysis Population: all participants enrolled in the study who received at least 1 dose of study treatment (INCB001158 or daratumumab subcutaneous \\[SC\\]). Participants were to be analyzed according to the treatment they were assigned to.","reportingStatus":"POSTED","timeFrame":"up to 454 days","title":"Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)","type":"PRIMARY","unitOfMeasure":"Participants"}